---
title: "Retatrutide Recomp: The Complete Stack for Preserving Muscle During Aggressive Fat Loss"
description: "Retatrutide delivers 24% weight loss but burns muscle without support. This evidence-based stack protocol preserves lean mass while maximizing fat loss through metabolic axis optimization."
date: "2025-11-07"
lastmod: "2025-11-07"
status: "draft"
tags: ['Retatrutide', 'Body Recomposition', 'GLP-1', 'Muscle Preservation', 'Fat Loss']
---

# Retatrutide Recomp: The Complete Stack for Preserving Muscle During Aggressive Fat Loss

> **Clinical Review Pending**
>
> This content is pending medical review by a licensed healthcare professional.
>
> Consult a qualified clinician before making any medical decisions based on this information.

## The Problem: Retatrutide's Double-Edged Sword

You're on retatrutide—or considering it—because the data is undeniable. The 48-week Phase 2 trial showed adults lost up to **24% of baseline body weight**, surpassing both semaglutide (~15%) and tirzepatide (~21%)[^1]. It's the most powerful metabolic intervention available.

But there's a catch that most people discover too late: **retatrutide doesn't just burn fat—it burns everything.**

Unlike dual-agonist GLP-1/GIP therapies, retatrutide activates a third pathway: **glucagon receptors**. Glucagon raises your basal metabolic rate and actively breaks down stored fat through lipolysis[^2]. This triple mechanism creates unprecedented appetite suppression and fat mobilization.

The problem? Glucagon pulls energy from **all tissues** without discriminating between fat and muscle. During aggressive caloric restriction—which retatrutide enforces through powerful appetite suppression—your body enters a catabolic state that threatens lean mass. You're losing weight fast, but you're also losing the muscle you worked years to build.

This is where most people using retatrutide alone hit a wall: they achieve dramatic weight loss but emerge with a "skinny-fat" physiology—lower weight but poor body composition, reduced strength, and a metabolism that's now primed to regain fat.

**The solution isn't to abandon retatrutide. It's to protect what matters while it does its work.**

---

## The Stack That Fixes It

The protocol below synchronizes six compounds designed to **preserve muscle and mitochondrial function** while retatrutide handles fat loss. Each one targets a specific vulnerability created by triple-agonist therapy:

### L-Carnitine (1.5–2g daily)
**Role:** Fat transport and utilization

Retatrutide liberates fat from adipose tissue, but that fat needs to reach mitochondria to be burned. L-Carnitine shuttles long-chain fatty acids across the mitochondrial membrane where they undergo beta-oxidation[^3]. Without adequate carnitine, liberated fat circulates without being oxidized—creating metabolic inefficiency.

A 37-trial meta-analysis confirmed L-carnitine supplementation produces modest but consistent reductions in body weight and fat mass[^4], supporting its role in fat utilization during caloric restriction.

### MOTS-c (5–10mg, 3x/week)
**Role:** Metabolic flexibility and AMPK activation

MOTS-c is a mitochondrial-derived peptide that activates AMPK—the cellular energy sensor governing fuel selection. It improves glucose uptake in muscle tissue and enhances insulin sensitivity, ensuring that the limited calories you're consuming preferentially feed muscle rather than being wasted[^5].

Research shows MOTS-c promotes metabolic homeostasis and reduces obesity while preserving lean tissue[^6]. During retatrutide's enforced caloric deficit, this ensures your muscles remain metabolically active and responsive.

### Tesamorelin (1–2mg daily)
**Role:** Anabolic protection and visceral fat targeting

Tesamorelin is a growth-hormone-releasing factor that stimulates endogenous GH pulses. Unlike exogenous GH, it preserves the body's natural feedback loops. Clinical trials demonstrate tesamorelin reduces visceral adipose tissue (VAT) by 15-20% without impairing glucose metabolism[^7][^8].

Critically, GH pulses create an anabolic environment that signals muscle preservation even during caloric restriction. This counterbalances retatrutide's catabolic pressure.

### AOD-9604 (300–500mcg daily)
**Role:** Selective lipolysis without GH effects

AOD-9604 is a modified C-terminal fragment of growth hormone that retains fat-mobilizing properties without affecting IGF-1 or blood glucose[^9]. It specifically targets stubborn adipose deposits—subcutaneous lower-body fat and visceral stores that resist conventional dieting.

Human safety studies confirm good tolerability with no impact on IGF-1 levels or insulin sensitivity[^10], making it a precise tool for fat mobilization that complements retatrutide's broader metabolic effects.

### NAD+ Precursors (NMN or NR, 500–1000mg daily)
**Role:** Energy production and cellular repair

Retatrutide's dramatic metabolic shift places enormous demand on mitochondrial ATP production. NAD+ is the primary electron carrier in cellular respiration. Supplementing with precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) ensures mitochondria have the cofactors needed to sustain energy production during caloric restriction.

NAD+ also supports DNA repair, circadian rhythm regulation, and sirtuin activation—all of which are stressed during aggressive weight loss.

### SS-31 (Elamipretide, 5–10mg, 3x/week)
**Role:** Mitochondrial membrane protection

SS-31 is a mitochondrial-targeted peptide that stabilizes cardiolipin—a phospholipid critical to inner mitochondrial membrane integrity. During periods of metabolic stress (like retatrutide-induced caloric restriction), mitochondria become vulnerable to oxidative damage and decreased efficiency.

SS-31 preserves mitochondrial function, reduces reactive oxygen species, and maintains ATP production capacity. This ensures your muscles retain their metabolic machinery even as retatrutide drives aggressive fat loss.

---

## How The System Works

Now that you understand what each compound does, here's how they work together with retatrutide's triple-receptor mechanism:

### The Triple Receptor Command Signal

Retatrutide activates three distinct pathways simultaneously[^2]:

**GLP-1 Receptors (Hypothalamus & Gut)**
Suppress appetite and create satiety. GLP-1 reduces "food noise"—the constant mental background of cravings and food thoughts. Meals become satisfying at smaller portions. Energy feels stable rather than oscillating between blood sugar spikes and crashes.

**GIP Receptors (Pancreas & Adipose)**
Fine-tune nutrient partitioning. GIP helps preserve insulin responsiveness during caloric restriction and influences how the limited calories you consume are distributed between muscle and fat tissue.

**Glucagon Receptors (Liver & Adipose)**
This is the differentiator. Glucagon raises basal metabolic rate—you burn more calories at rest—and actively mobilizes stored fat through lipolysis. It targets visceral fat and hepatic (liver) fat, the metabolically harmful deposits that resist conventional dieting.

The mechanism involves:
1. **AMPK activation** (cellular energy sensor promoting fat oxidation)
2. **UCP-1 upregulation** (uncoupling protein-1 for thermogenesis)
3. **mTOR inhibition** during daytime (preventing wasteful growth signaling during catabolic phases)

### The Cascade: Protection Layers

Here's how the support stack creates multiple protection layers:

```
RETATRUTIDE (Fat Mobilization)
    ↓
L-CARNITINE → Transports freed fat to mitochondria
    ↓
MOTS-c → Activates AMPK, ensures muscle glucose uptake
    ↓
SS-31 → Protects mitochondrial function under stress
    ↓
NAD+ → Provides energy cofactors for ATP production
    ↓
TESAMORELIN → Anabolic GH pulses preserve muscle
    ↓
AOD-9604 → Targets stubborn fat retatrutide might miss
    ↓
RESULT: Maximum fat loss, preserved lean mass
```

Each layer addresses a specific vulnerability. Without this synchronized approach, retatrutide's power becomes a liability—rapid weight loss at the expense of metabolic health.

---

## The Complete Protocol

**This is a single intermediate protocol designed for individuals on retatrutide or similar GLP-1 agonists who want to preserve muscle during aggressive fat loss.**

### Morning Stack (Fasted or With Light Breakfast)

**7:00 AM – Catabolic Window**
- L-Carnitine: 1.5–2g (oral)
- NAD+ precursor (NMN/NR): 500–1000mg

**Purpose:** Support fat oxidation and energy production during the daytime AMPK-dominant metabolic phase.

**9:00 AM (Monday/Wednesday/Friday)**
- MOTS-c: 5–10mg subcutaneous
- SS-31: 5–10mg subcutaneous

**Purpose:** Enhance metabolic flexibility and protect mitochondria during peak catabolic stress.

### Evening Stack (Before Bed)

**10:00 PM – Anabolic Window**
- Tesamorelin: 1–2mg subcutaneous
- AOD-9604: 300–500mcg subcutaneous

**Purpose:** Create anabolic GH pulse during nighttime mTOR-dominant recovery phase, target stubborn fat deposits.

### Retatrutide Dosing (Separate from Stack)

Follow your prescribed retatrutide titration protocol. Typical medical protocols:
- Weeks 1-4: 2mg weekly
- Weeks 5-8: 4mg weekly
- Weeks 9-12: 8mg weekly (if tolerated)
- Maintenance: 8-12mg weekly

**Ultra-slow titration reduces side effects.** Many users benefit from staying at 4mg for 8 weeks before advancing.

### Monitoring Requirements

**Weekly:**
- Body weight (same time, same conditions)
- Waist circumference at navel
- Subjective energy and hunger levels (1-10 scale)

**Bi-weekly:**
- Body composition scan (DEXA or InBody)
- Strength metrics (track key lifts)

**Monthly:**
- Fasting glucose and HbA1c
- Lipid panel
- Liver enzymes (AST/ALT)
- TSH and free T3 (thyroid function)

**Red flags requiring dose adjustment or pause:**
- Strength loss >15% on key lifts
- Lean mass loss >2% over 2-week period
- Persistent lethargy despite adequate sleep
- Elevated liver enzymes (>2x upper normal)
- Heart rate >100 resting or new palpitations

---

## Timeline: What to Expect

### Weeks 1-4: Adaptation Phase
**Retatrutide effects:** Appetite suppression kicks in. Initial water weight loss (5-8 lbs).
**Stack effects:** L-Carnitine and NAD+ improve energy. MOTS-c begins enhancing insulin sensitivity.
**Body composition:** Expect 2-3% body fat reduction with minimal lean mass loss if protocol followed correctly.

### Weeks 5-8: Peak Fat Loss Phase
**Retatrutide effects:** Appetite almost fully suppressed. Dramatic fat loss acceleration.
**Stack effects:** Tesamorelin creates visible muscle fullness despite caloric deficit. AOD-9604 targets stubborn lower-body fat.
**Body composition:** 4-6% additional fat loss. Muscle fullness maintained or improved due to anabolic support.

### Weeks 9-12: Refinement Phase
**Retatrutide effects:** Weight loss rate stabilizes but remains consistent.
**Stack effects:** SS-31 and NAD+ become critical as mitochondria adapt to sustained caloric restriction.
**Body composition:** 3-4% additional fat loss, increasingly from visceral and stubborn subcutaneous depots.

### Weeks 13-24: Maintenance Recomp
**Retatrutide effects:** Transition to maintenance dose (8-12mg weekly).
**Stack effects:** Continue full support stack or transition to L-Carnitine + NAD+ maintenance with periodic MOTS-c/Tesamorelin pulses.
**Body composition:** Focus shifts from aggressive fat loss to lean mass preservation and metabolic flexibility.

**Expected total outcome (24 weeks):** 12-18% total fat loss with 90-95% lean mass retention—dramatically better than retatrutide alone.

---

## Safety, Side Effects, and When to Stop

> **⚠️ Medical Supervision Required**
>
> The protocols described in this article should only be undertaken under the supervision of a qualified healthcare provider.
>
> Self-administration without medical oversight may pose serious health risks.

### Common Side Effects (Manageable)

**Retatrutide:**
- Nausea (weeks 1-3, improves with ultra-slow titration)
- Constipation (increase fiber and hydration)
- Fatigue (NAD+ and electrolytes help)
- Injection site reactions (rotate sites, use insulin syringes)

**Support Stack:**
- Mild injection site redness (normal, resolves in 24 hours)
- Transient headaches from NAD+ (start lower dose, titrate up)
- Carnitine: fishy odor in some individuals (dose-dependent)

### Serious Warning Signs (Stop Immediately)

**Cardiovascular:**
- Resting heart rate >100 bpm
- New heart palpitations or arrhythmia feeling
- Chest pain or pressure

**Metabolic:**
- Severe nausea/vomiting preventing hydration
- Signs of pancreatitis (severe upper abdominal pain radiating to back)
- Persistent hypoglycemia (<70 mg/dL with symptoms)

**Endocrine:**
- Signs of thyroid dysfunction (new intolerance to cold, severe fatigue, depression)
- Severe water retention or facial swelling

**Musculoskeletal:**
- Strength loss >20% over 2-week period despite full stack
- Muscle cramps or fasciculations
- Joint pain (possible GH-related fluid retention)

### When to Freeze Dose or Pause

**Freeze retatrutide dose (don't advance) if:**
- Nausea interferes with work or daily function
- Energy levels consistently <5/10
- Lean mass declining >1% every 2 weeks
- Liver enzymes elevated but <2x upper limit

**Pause entire protocol if:**
- Any serious warning signs above
- Pregnant or planning pregnancy
- Active thyroid disorder (medullary thyroid cancer risk)
- History of pancreatitis
- Severe kidney or liver disease

### Who Should Avoid This Protocol

**Absolute contraindications:**
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- Pregnancy or breastfeeding
- Active eating disorder
- Severe depression or suicidal ideation (GLP-1 agonists have rare psychiatric effects)

**Relative contraindications (requires specialist oversight):**
- Type 1 diabetes
- History of pancreatitis
- Severe gastroparesis
- Diabetic retinopathy (rapid glucose changes can worsen)
- Kidney disease (CrCl <30 mL/min)

---

## Why This Works: The Metabolic Rebalancing

Retatrutide without support creates a metabolic crisis:
- Extreme caloric deficit (often 50-70% below baseline)
- Accelerated catabolism from glucagon activation
- Mitochondrial stress from sustained energy deficit
- Loss of anabolic signaling (low IGF-1, suppressed mTOR)

**The result:** Rapid weight loss, but muscle loss, metabolic slowdown, and eventual plateau.

This protocol does something different: it **accepts retatrutide's catabolic power** while building protective anabolic layers:

1. **Energy substrate optimization** (L-Carnitine, NAD+): Ensures fat—not muscle—fuels metabolism
2. **Metabolic signaling** (MOTS-c): Preserves insulin sensitivity and glucose partitioning to muscle
3. **Mitochondrial protection** (SS-31): Maintains cellular energy machinery under stress
4. **Anabolic counter-signaling** (Tesamorelin): Creates GH pulses that tell muscles to stay
5. **Targeted lipolysis** (AOD-9604): Mobilizes stubborn fat without systemic catabolic pressure

The result is **true body recomposition**: you lose fat at retatrutide's unprecedented rate while preserving—or even building—the metabolic machinery that keeps you healthy and strong.

---

## Next Steps: Getting Started Safely

**Step 1: Medical Supervision**
Find a physician experienced with peptide protocols and GLP-1 agonist therapy. Baseline labs (metabolic panel, lipids, HbA1c, thyroid, liver enzymes) are mandatory.

**Step 2: Source Quality Compounds**
Use only pharmaceutical-grade or research-grade peptides from verified suppliers with certificates of analysis (CoA). Contaminated or underdosed peptides create safety risks and poor outcomes.

**Step 3: Begin Retatrutide Titration**
Start at 2mg weekly. Do not rush titration. Many people achieve excellent results at 4-8mg without advancing to higher doses.

**Step 4: Layer Support Stack Gradually**
Week 1-2: Add L-Carnitine and NAD+ (oral, easiest to start)
Week 3-4: Add MOTS-c and SS-31 (injectable, 3x/week)
Week 5+: Add Tesamorelin and AOD-9604 (evening protocol)

**Step 5: Track Everything**
Use a spreadsheet or app to log:
- Daily weight (same time, fasted)
- Weekly strength metrics
- Bi-weekly body composition
- Monthly labs
- Side effect severity (0-10 scale)

**This data determines when to advance, freeze, or pause.**

---

## Conclusion: Recomposition Without Compromise

Retatrutide represents a breakthrough in metabolic intervention—24% weight loss is transformative[^1]. But weight loss without muscle preservation is a pyrrhic victory. You'll be lighter, but weaker, with a slower metabolism and poor body composition.

This protocol is designed for people who refuse to accept that trade-off. You want the fat loss retatrutide delivers, but you also want to keep—or build—the muscle that defines strength, metabolic health, and physical capability.

The stack isn't optional if you're serious about recomposition. Each compound addresses a specific vulnerability created by triple-agonist therapy. Together, they create a system where aggressive fat loss coexists with muscle preservation.

**This is what body recomposition actually looks like: not choosing between fat loss and muscle gain, but engineering a metabolic environment where both can happen simultaneously.**

If you're on retatrutide or planning to start, now you know how to do it right.

---

## References

[^1]: Jastreboff AM, Aronne LJ, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. *New England Journal of Medicine*. 2023. [https://doi.org/10.1056/NEJMoa2301972](https://doi.org/10.1056/NEJMoa2301972)

[^2]: Thomas MK, Nikooienejad A, et al. Efficacy and safety of Retatrutide, a novel GLP-1, GIP and glucagon receptor agonist. *Nature Medicine*. 2024. [https://doi.org/10.1038/s41591-024-03018-2](https://doi.org/10.1038/s41591-024-03018-2)

[^3]: Fielding R, Riede L, et al. L-Carnitine Supplementation in Recovery after Exercise. *Nutrients*. 2018.

[^4]: Pooyandjoo M, Nouhi M, et al. Effect of L-Carnitine Supplementation on Weight Loss and Body Composition: Systematic Review and Meta-Analysis. *Clinical Nutrition*. 2020. [https://pubmed.ncbi.nlm.nih.gov/32359762/](https://pubmed.ncbi.nlm.nih.gov/32359762/)

[^5]: Lee C, Zeng J, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. *Cell Metabolism*. 2015. [https://doi.org/10.1016/j.cmet.2015.02.009](https://doi.org/10.1016/j.cmet.2015.02.009)

[^6]: Lu H, Tang S, et al. Mitochondria-Derived Peptide MOTS-c: Effects and Mechanisms. *Journal of Translational Medicine*. 2023. [https://doi.org/10.1186/s12967-023-03885-2](https://doi.org/10.1186/s12967-023-03885-2)

[^7]: Stanley TL, Chen CY, et al. Safety and metabolic effects of tesamorelin, a growth-hormone-releasing factor in obese subjects. *Metabolism*. 2014. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513535/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513535/)

[^8]: Stanley TL, Falutz J, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation. *JAMA*. 2014. [https://pubmed.ncbi.nlm.nih.gov/25038357/](https://pubmed.ncbi.nlm.nih.gov/25038357/)

[^9]: Heffernan MA, Thorburn AW, et al. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone. *Endocrinology*. 2001. [https://pubmed.ncbi.nlm.nih.gov/11146367/](https://pubmed.ncbi.nlm.nih.gov/11146367/)

[^10]: Kharitonenkov A, Dunbar JD, et al. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. *Journal of Endocrinology and Metabolism*. 2013. [https://jofem.org/index.php/jofem/article/view/157](https://jofem.org/index.php/jofem/article/view/157)

---

_Disclaimer: Educational content only. Consult a licensed clinician before making changes to diagnosis or treatment._

_**Disclaimer:** This content is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed healthcare provider before making any changes to your medical treatment or supplementation regimen._
